The 16 Days of Activism Against Gender-Based Violence against women is an international campaign from November 25-December 10. Read more about the campaign's goals and where to access additional resources and support.
Gender
News
November 9, 2020
The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.
Opportunity
November 5, 2020
Panagora Group's South Africa office is looking for a service provider to conduct a comprehensive salary survey for professional roles in South Africa.
Opportunity
October 26, 2020
Panagora Group's South Africa office is looking for an accredited South African university to partner in a mental health research study.
Resource
October 21, 2020
An inclusive summit for multidisciplinary experts working with adolescents affected by HIV, which will be held as a series of virtual workshops throughout the month of November. Topics will include youth leadership, mental health and psychosocial support interventions, participatory research approaches, and Mhealth and new technologies, among others.
Resource
October 12, 2020
Introduction
Young women in Southern Africa have extremely high HIV incidence rates necessitating the availability of female‐controlled prevention methods.
News
October 9, 2020
Sex workers continue to demand decriminilisation, saying outdated lawscontribute to their abuse at the hands of police, and discrimination in society.
Resource
October 8, 2020
The DREAMS initiative is a PEPFAR-funded programme that uses a multi-sectoral approach to prevent HIV/AIDS among adolescent girls and young women (AGYW) and their male sex partners (MSPs).
Resource
October 8, 2020
Introduction
Men who have sex with men (MSM) and transgender women (TGW) are at increased risk for acquiring HIV, but there are limited HIV incidence data for these key populations in Africa.
Resource
October 8, 2020
Introduction
Some observational data suggest that the progestogen injectable contraceptive depot medroxyprogesterone acetate (DMPA) may increase a woman’s risk of HIV acquisition but a randomized clinical trial did not find a statistically significant incre
